Research Article: Risk of Subsequent Breast Cancer in Women with Early Stage HER-Positive Breast Cancer in a Large Community Health Plan
Introduction:
About –% of breast cancers have amplification of the human epidermal growth factor receptor (HER) gene or HER protein overexpression (“HER-positive”), which is associated with poor clinical outcomes. Following the demonstration that trastuzumab, a humanized monoclonal antibody that binds close to the trans-membrane domain of the HER protein, resulted in improved survival in HER-positive metastatic breast cancer in combination with chemotherapy, clinical trials of adjuvant trastuzumab were initiated. In , early…
Read more